Are we overlooking wearing off? Evaluating the role of the WOQ-9 questionnaire in routine Parkinson’s care
Objective: 1. Evaluate clinicians’ ability to recognise wearing-off compared with the Wearing Off Questionnaire-9 (WOQ-9)2. Assess patient awareness of wearing-off symptoms Background: Wearing off is…Association of DAGLB Variants with Early-Onset Parkinson’s Disease Across Populations
Objective: Here, we investigated the contribution of DAGLB variants to PD across diverse ancestries using large-scale data from the Global Parkinson’s Genetics Program (GP2). Background:…Augmenting PD GENEration Genotyping with Continuous Digital Monitoring for Parkinson’s Disease
Objective: To link PD GENEration genetic testing and counseling with continuous digital phenotyping to characterize genotype-associated mobility change, reduce access barriers, and support recruitment for…Serum Zinc Reduction During Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson’s Disease
Objective: To investigate whether continuous subcutaneous foslevodopa/foscarbidopa infusion reduces serum zinc levels in patients with Parkinson’s disease. Background: Reduced serum zinc levels in Parkinson’s disease…Phase 2 Trial for the Treatment of Early-stage Parkinson’s Disease with TJ0113, a Small Molecule Mitophagy Activator
Objective: To investigate the efficacy and safety of TJ0113 for patients with early-stage Parkinson's disease. Background: Mitochondrial dysfunction, particularly decreased mitophagy, may contribute to the pathogenesis of…Functional Intramuscular Stimulation for Pain in Parkinson’s Disease and Sporadic Amyotrophic Lateral Sclerosis: A Retrospective Case Series
Objective: To describe clinical characteristics and short-term pain outcomes after functional intramuscular stimulation (FIMS) in patients with Parkinson's disease or sporadic amyotrophic lateral sclerosis. Background:…Real-world variability in dosing of continuous subcutaneous foslevodopa/foscarbidopa infusion in advanced Parkinson’s disease: evidence from a single-center cohort
Objective: To evaluate dosing patterns, demographic characteristics, and safety outcomes in patients with advanced Parkinson's Disease (PD) treated with continuous subcutaneous foslevodopa/foscarbidopa infusion in routine…A Genome-Wide Search for Common Variants Modifying Age at Onset in PRKN-Associated Parkinson’s Disease
Objective: The aim of this study was to identify potential genetic modifiers of age at onset in PRKN-associated Parkinson's disease (PD) through a genome-wide association…Predicting Levodopa Responsiveness in Early Parkinson’s Disease Using Neural Perturbation Inference-Based Effective Connectivity
Objective: To investigate the brain network mechanisms underlying individual variability in levodopa responsiveness in Parkinson’s disease (PD) and to evaluate the predictive value of baseline…Age-Modulated Gait Adaptations to Progressive Fatigue in Parkinson’s Disease
Objective: To investigate the effect of progressively increasing perceived fatigue on gait biomechanics in people with Parkinson’s disease (PD), considering the potential moderating role of…
- « Previous Page
- 1
- …
- 106
- 107
- 108
- 109
- 110
- …
- 553
- Next Page »